CJEU clarifies ‘basic patent’ meaning in SPC dispute

Earlier today, the Court of Justice of the European Union (CJEU) clarified when a product is ‘protected by a basic patent’ within the meaning of article 3(a) of regulation 469/2009 (the SPC regulation).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

CJEU hands down SPC guidance in Royalty Pharma

30 April 2020 The Court of Justice of the European Union has handed down its decision in Royalty Pharma, providing highly-anticipated guidance on supplementary protection certificates.

Big Pharma

German patent court publishes reasoning in Gilead SPC dispute

6 November 2018 Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,

Big Pharma

SPC waiver proposal could discourage innovation, says pharma group

9 August 2018 A proposed change to supplementary protection certificate rules in the EU could lead to the development of less innovative medicines, according to the Irish Pharmaceutical Healthcare Association.

More features

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

CJEU clarifies ‘basic patent’ meaning in SPC dispute

More on this story

Editor's picks

Editor's picks

More features